Bill Gross warns on gold momentum as regional bank stocks tumble
Investing.com - Piper Sandler has reiterated its Overweight rating and $65.00 price target on Supernus Pharmaceuticals (NASDAQ:SUPN), a pharmaceutical company with an impressive 88.5% gross profit margin and strong market performance, following a webinar with a movement disorder specialist. According to InvestingPro data, the stock has surged over 61% in the past six months and currently trades near its 52-week high of $51.78.
The research firm hosted a discussion with a leading Parkinson’s disease specialist that focused on recently launched continuous subcutaneous infusion treatments, including Supernus’ Onapgo and AbbVie’s (NYSE:ABBV) Vyalev.
The medical expert described the category of continuous subcutaneous infusion pumps as "transformative" and positioned them as alternatives to deep brain stimulation, which has historically been a key part of the specialist’s practice.
According to Piper Sandler, the specialist expressed a preference for Onapgo, Supernus’ apomorphine-based continuous subcutaneous infusion pump, over competing products.
The firm views Onapgo as a potential source of further multiple expansion for Supernus, referencing its upgrade note on October 8, 2025, which provided additional details on this assessment.
In other recent news, Supernus Pharmaceuticals reported its second-quarter 2025 earnings, showcasing a revenue of $165 million, which exceeded the consensus estimate of $154.3 million. Despite this revenue beat, the company’s earnings per share (EPS) came in at $0.40, missing the projected $0.48. This mixed financial performance reflects a strong revenue growth driven by products like Qelbree and Gocovri. Additionally, Stifel raised its price target for Supernus Pharmaceuticals to $43 from $38, maintaining a Hold rating, following the company’s robust quarterly results.
Analyst firms have been adjusting their outlooks for Supernus Pharmaceuticals, with Piper Sandler upgrading the stock from Neutral to Overweight. This upgrade is based on the reassessment of the sales potential for Onapgo, Supernus’s infusion pump for advanced Parkinson’s disease, with U.S. peak sales projected to exceed $300 million. Similarly, Cantor Fitzgerald raised its price target to $63 from $46, citing a faster-than-expected adoption rate for Onapgo. These developments highlight the positive sentiment among analysts regarding Supernus’s future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.